Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

NYSE:ATNM opened at $1.29 on Friday. Actinium Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $10.24. The business’s 50-day simple moving average is $1.31. The company has a ...

Under the terms of the agreement, ITM will supply the therapeutic medical radioisotope, Ac-225, produced by Actineer™ Inc, ITM's joint venture company with Canadian Nuclear Laboratories, for use in ...